Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT"), a life sciences company
developing stem cell-related technologies, today announced that it has completed
its merger with Trillium Therapeutics Inc. ("Trillium") previously announced on
February 4, 2013. The shareholders of Trillium voted overwhelmingly to support
the merger.


The company also announced the issuance of 2,560,197 stock options under its
stock option plan to directors, officers and employees reflecting the addition
of the executives and staff of the merged entity. The options have an exercise
price of $0.25 and a term of ten years. The issuance of stock options is subject
to acceptance by the TSX Venture exchange.


About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) develops stem cell-based
therapeutics through partnerships with research institutions and technology
transfer organizations. SCT's objectives include the sourcing and acquisition of
stem cell-related development opportunities, and securing capital for the
advancement of its licensed or acquired products. The Corporation's intended
corporate acquisitions and licensed acquisitions are positioning it principally
in the field of cancer stem cell therapeutic development. SCT is a member of the
Centre for Commercialization of Regenerative Medicine consortium. For more
information, visit: www.stemcellthera.com.


Forward Looking Statements

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, but are not limited to, the satisfaction of the conditions
precedent to the exercise of the option to acquire a license to certain
technologies owned by University Health Network; the exercise of the option to
acquire a license to certain technologies owned by University Health Network;
the execution and delivery of a definitive license agreement with University
Health Network if SCT determines to exercise the University Health Network
option; changing market conditions; the successful and timely completion of
pre-clinical and clinical studies; the establishment of corporate alliances; the
impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting, including in the base shelf prospectus dated March 1, 2011 and any
prospectus supplement. Except as required by applicable securities laws, SCT
undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
Niclas Stiernholm
Chief Executive Officer
+1 416 595 0627
nstiernholm@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Sunvest Minerals Corp Charts.
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Sunvest Minerals Corp Charts.